These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26528756)

  • 1. Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.
    Chang YW; Hsieh PW; Chang YT; Lu MH; Huang TF; Chong KY; Liao HR; Cheng JC; Tseng CP
    Oncotarget; 2015 Dec; 6(40):42733-48. PubMed ID: 26528756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
    Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
    J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
    Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
    Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysaccharide-containing fraction from Artemisia argyi inhibits tumor cell-induced platelet aggregation by blocking interaction of podoplanin with C-type lectin-like receptor 2.
    Tseng CP; Huang YL; Chang YW; Liao HR; Chen YL; Hsieh PW
    J Food Drug Anal; 2020 Jan; 28(1):115-123. PubMed ID: 31883599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The podoplanin-CLEC-2 interaction promotes platelet-mediated melanoma pulmonary metastasis.
    Sheng M; Sun R; Fu J; Lu G
    BMC Cancer; 2024 Apr; 24(1):399. PubMed ID: 38561690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
    Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
    J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of C-type lectin-like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides.
    Delierneux C; Donis N; Servais L; Wéra O; Lecut C; Vandereyken M; Musumeci L; Rahmouni S; Schneider J; Eble JA; Lancellotti P; Oury C
    J Thromb Haemost; 2017 May; 15(5):983-997. PubMed ID: 28296036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification of the novel platelet activation receptor CLEC-2 and Its pathological and physiological roles].
    Suzuki Inoue K; Inoue O; Ozaki Y
    Rinsho Byori; 2010 Dec; 58(12):1193-202. PubMed ID: 21348239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    Xu M; Wang X; Pan Y; Zhao X; Yan B; Ruan C; Xia L; Zhao Y
    BMC Cancer; 2019 Jun; 19(1):599. PubMed ID: 31208371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cobalt hematoporphyrin inhibits CLEC-2-podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice.
    Tsukiji N; Osada M; Sasaki T; Shirai T; Satoh K; Inoue O; Umetani N; Mochizuki C; Saito T; Kojima S; Shinmori H; Ozaki Y; Suzuki-Inoue K
    Blood Adv; 2018 Sep; 2(17):2214-2225. PubMed ID: 30190281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
    Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
    Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diphenyl-tetrazol-propanamide Derivatives Act as Dual-Specific Antagonists of Platelet CLEC-2 and Glycoprotein VI.
    Watanabe N; Shinozaki Y; Ogiwara S; Miyagasako R; Sasaki A; Kato J; Suzuki Y; Fukunishi N; Okada Y; Saito T; Iida Y; Higashiseto M; Masuda H; Nagata E; Gotoh K; Amino M; Tsuji T; Morita S; Nakagawa Y; Hirayama N; Inokuchi S
    Thromb Haemost; 2024 Mar; 124(3):203-222. PubMed ID: 37967855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
    Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
    J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.
    Hwang BO; Park SY; Cho ES; Zhang X; Lee SK; Ahn HJ; Chun KS; Chung WY; Song NY
    Front Immunol; 2021; 12():807600. PubMed ID: 34987523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.
    Suzuki-Inoue K
    Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-type lectin-like receptor-2 (CLEC-2) is a key regulator of kappa-carrageenan-induced tail thrombosis model in mice.
    Yokomori R; Shirai T; Tsukiji N; Oishi S; Sasaki T; Takano K; Suzuki-Inoue K
    Platelets; 2023 Dec; 34(1):2281941. PubMed ID: 38010137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
    Suzuki-Inoue K
    J Biochem; 2011 Aug; 150(2):127-32. PubMed ID: 21693546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis.
    Inoue O; Hokamura K; Shirai T; Osada M; Tsukiji N; Hatakeyama K; Umemura K; Asada Y; Suzuki-Inoue K; Ozaki Y
    PLoS One; 2015; 10(9):e0139357. PubMed ID: 26418160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation of threonine 34 in mouse podoplanin-Fc reduces CLEC-2 binding and toxicity in vivo while retaining antilymphangiogenic activity.
    Bianchi R; Fischer E; Yuen D; Ernst E; Ochsenbein AM; Chen L; Otto VI; Detmar M
    J Biol Chem; 2014 Jul; 289(30):21016-27. PubMed ID: 24907275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.